Skip to content

Multiomics-based biomarkers for early detection and prognostic monitoring of lung cancer

The screening and clinical application of multiomics-based biomarkers for early detection and prognostic monitoring of lung cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036938
Enrollment
Unknown
Registered
2020-08-25
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

Gold Standard:The gold standard for lung cancer diagnosis currently relies on histopathological detection, and recurrence monitoring currently relies mainly on clinical imaging (such as CT follow-up).
(fluid&#32
protein&#32
and&#32
epigenetic).

Sponsors

Shanghai Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Lung cancer patients receiving treatment in Shanghai chest hospital; (2) Diagnose with lung cancer by pathology; (3) Patients with clinical TNM stage I- IIIa; (4) underwent chest CT scan before treatment ; (5) Blood samples have been collected and preserved before treatment.

Exclusion criteria

Exclusion criteria: (1) Previous history of other malignant tumors; (2) Patient with distant metastases; (3) Pneumonectomy for other reasons; (4) Patients with serious heart disease, lung dysfunction; (5) Those who have previously received anti-tumor therapy; (6) The investigator believes that it is not suitable for other situations in this trial.

Design outcomes

Primary

MeasureTime frame
sensitivity;specificity;specificity;positive predictive value;negative predictive value;

Countries

China

Contacts

Public ContactJiatao Lou

Shanghai Chest Hospital

loujiatao@126.com+86 18616593001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026